Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World dupixent study shows promise for eczema sufferers

NCT ID NCT06099704

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen May 20, 2026 · Last updated May 23, 2026 · Updated 1 time

Summary

This study followed 305 Canadian patients aged 6 and older with moderate-to-severe atopic dermatitis (eczema) who were prescribed Dupixent as part of their routine care. Researchers measured how many patients saw at least a 75% improvement in their eczema symptoms after 6, 12, and 18 months. The goal was to see how well the treatment works in everyday life, not just in a controlled trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Investigational Site Number : 1240002

    Ajax, Ontario, L1S 7K8, Canada

  • Investigational Site Number : 1240003

    Regina, Saskatchewan, S4V 1R9, Canada

  • Investigational Site Number : 1240005

    Richmond Hill, Ontario, L4E 4L6, Canada

  • Investigational Site Number : 1240006

    Pointe-Claire, Quebec, H9R 5M7, Canada

  • Investigational Site Number : 1240007

    Edmonton, Alberta, T5K 1X3, Canada

  • Investigational Site Number : 1240008

    Peterborough, Ontario, K9J5K2, Canada

  • Investigational Site Number : 1240009

    Edmonton, Alberta, T5J 3S9, Canada

  • Investigational Site Number : 1240010

    Surrey, British Columbia, V3R 6A7, Canada

  • Investigational Site Number : 1240011

    Etobicoke, Ontario, M8X 1Y9, Canada

  • Investigational Site Number : 1240012

    Montreal, Quebec, H3H 2R9, Canada

  • Investigational Site Number : 1240013

    Québec, G1W 4R4, Canada

  • Investigational Site Number : 1240014

    Toronto, Ontario, M5G 1X8, Canada

  • Investigational Site Number : 1240015

    Toronto, Ontario, M5G 1E2, Canada

  • Investigational Site Number : 1240016

    London, Ontario, N6A 5R9, Canada

  • Investigational Site Number : 1240017

    Montreal, Quebec, H3T 1C5, Canada

  • Investigational Site Number : 1240018

    Waterloo, Ontario, N2J 1C4, Canada

  • Investigational Site Number : 1240019

    Calgary, Alberta, T2J 7E1, Canada

  • Investigational Site Number : 1240020

    Halifax, Nova Scotia, B3H 4R2, Canada

  • Investigational Site Number : 1240021

    Calgary, Alberta, T3B 6A8, Canada

  • Investigational Site Number : 1240023

    Saint-Jean-sur-Richelieu, Quebec, J3A 1B5, Canada

  • Investigational Site Number : 1240024

    Barrie, Ontario, L4M 7G1, Canada

  • Investigational Site Number : 1240025

    Newmarket, Ontario, L3Y 5G8, Canada

  • Investigational Site Number : 1240026

    Fredericton, New Brunswick, E3B 1G9, Canada

  • Investigational Site Number : 1240027

    Saskatoon, Saskatchewan, S7K 2C1, Canada

  • Investigational Site Number : 1240028

    Nanaimo, British Columbia, V9V 1A3, Canada

  • Investigational Site Number : 1240029

    Winnipeg, Manitoba, R3M 3Z4, Canada

  • Investigational Site Number : 1240030

    Toronto, Ontario, M4E 1R7, Canada

  • Investigational Site Number : 1240031

    Cobourg, Ontario, K9A 0Z4, Canada

  • Investigational Site Number : 1240033

    Toronto, Ontario, M3B 0A7, Canada

  • Investigational Site Number : 1240034

    Whitby, Ontario, L1N 8M7, Canada

Conditions

Explore the condition pages connected to this study.

MODERATE TO SEVERE ATOPIC DERMATITIS